VA
UTHR icon

Vident Advisory’s United Therapeutics UTHR Stock Holding History

Vident Advisory’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.54M Buy
6,535
+496
+8% +$279K 0.03% 492
2026
Q1 		$3.58M Buy
6,039
+1,807
+43% +$900K 0.03% 448
2025
Q4 		$2.06M Sell
4,232
-1,276
-23% -$594K 0.02% 573
2025
Q3 		$2.31M Sell
5,508
-9,071
-62% -$3.05M 0.02% 526
2025
Q2 		$4.19M Sell
14,579
-3,162
-18% -$945K 0.05% 316
2025
Q1 		$5.47M Buy
17,741
+5,520
+45% +$1.89M 0.08% 218
2024
Q4 		$4.31M Buy
12,221
+1,596
+15% +$587K 0.08% 233
2024
Q3 		$3.81M Buy
10,625
+3,724
+54% +$1.26M 0.1% 215
2024
Q2 		$2.2M Buy
6,901
+1,806
+35% +$478K 0.06% 335
2024
Q1 		$1.17M Buy
5,095
+573
+13% +$129K 0.02% 531
2023
Q4 		$994K Buy
4,522
+1,818
+67% +$419K 0.03% 560
2023
Q3 		$611K Buy
+2,704
New +$623K 0.02% 644

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Vident Advisory's UTHR Position: Q2 2026 in Review

Vident Advisory increased its United Therapeutics (UTHR) stake by 8.2% in Q2 2026, buying an estimated $279K and bringing the position to 6,535 shares worth $3.54M. The position accounts for 0.03% of the portfolio, ranked #492.

Vident Advisory first reported a position in UTHR in Q3 2023 and has held it in 12 quarters since. The position peaked at $5.47M in Q1 2025. 884 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Vident Advisory held 6,535 shares of United Therapeutics worth $3.54M as of Q2 2026.
  • Vident Advisory bought 496 United Therapeutics shares in Q2 2026, an estimated $279K.
  • United Therapeutics made up 0.03% of Vident Advisory's portfolio in Q2 2026, its #492 holding.
  • Vident Advisory first reported a position in United Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • Vident Advisory's United Therapeutics position peaked at $5.47M in Q1 2025.
  • 884 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.